MYC and hepatocellular carcinoma: To further clarify the enhanced therapeutic efficacy of the combination treatment, we established an HCC animal model by hydrodynamic tail vein injection with SB13/c‐Myc/sgP53 and treated with ASO LINC01116, anti‐PD1 or the combination (Figure 8H).